LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.05

Buy Sell

Overview

Share price change

24h

Current

Min

1.04

Max

1.11

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+376.19% upside

Market Stats
By TradingEconomics
Market Cap	3.5M 129M
Previous open	1.05
Previous close	1.05

News Sentiment

By Acuity

26%

74%

53 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 gru 2025, 17:29 UTC

Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19 gru 2025, 16:47 UTC

Major Market Movers

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19 gru 2025, 16:10 UTC

Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

19 gru 2025, 22:33 UTC

Earnings

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19 gru 2025, 22:19 UTC

Earnings

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19 gru 2025, 21:48 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 21:44 UTC

Earnings

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 gru 2025, 21:38 UTC

Earnings

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19 gru 2025, 21:00 UTC

Market Talk

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19 gru 2025, 20:23 UTC

Market Talk

Oil Futures End Down Week on Up Note -- Market Talk

19 gru 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19 gru 2025, 18:38 UTC

Market Talk

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19 gru 2025, 18:00 UTC

Market Talk

Earnings

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19 gru 2025, 17:41 UTC

Earnings

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 gru 2025, 17:24 UTC

Market Talk

Earnings

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19 gru 2025, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

19 gru 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19 gru 2025, 16:29 UTC

Earnings

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19 gru 2025, 16:20 UTC

Acquisitions, Mergers, Takeovers

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19 gru 2025, 16:19 UTC

Acquisitions, Mergers, Takeovers

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19 gru 2025, 16:18 UTC

Acquisitions, Mergers, Takeovers

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19 gru 2025, 16:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 gru 2025, 16:16 UTC

Market Talk

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19 gru 2025, 16:05 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 16:04 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 15:37 UTC

Market Talk

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19 gru 2025, 15:21 UTC

Market Talk

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19 gru 2025, 15:09 UTC

Market Talk

Gold Flat But Set for Weekly Gains -- Market Talk

19 gru 2025, 15:09 UTC

Market Talk

Global Equities Roundup: Market Talk

19 gru 2025, 15:09 UTC

Earnings

FedEx Earnings Were Strong. The Stock Is Down. -- Barrons.com

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

376.19% upside

12 Months Forecast

Average 5 USD 376.19%

High 8 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

53 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.